Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

March 2, 2018: By Joan McKenna

Valeant reported Feb. 28 that its 2017 revenues totaled $8.72 billion, a 10 percent decrease from 2016 revenues of $9.67 billion.

The company said its Bausch + Lomb/International segment accounted for 56 percent of total revenues in 2017.

Valeant said its revenue decline was partially offset by higher volumes in the Bausch + Lomb/International segment, primarily the US Consumer Products business, and increased international pricing in the segment.

Bausch + Lomb posted 2017 revenues of $4.87 billion, a drop of 1 percent from 2016 revenues of $4.93 billion.

Bausch + Lomb’s Q4-2017 revenues were $1.23 billion, a decline of 3 percent from Q4-2016 revenues of $1.26 billion.

Valeant said it reduced its debt by more than $4.4 billion in 2017. It also reduced debt repayment requirements through 2020 by more than $10.8 billion since Dec. 31, 2016, and eliminated all long-term debt maturities until 2020 and all mandatory amortization requirements.

CEO Joseph C. Papa called 2017 “a year of strong progress for Valeant.”

The company provided guidance for 2018 of $8.10 billion to $8.30 billion in revenues.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023